We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Colon Cancer Risk Traced To Common Ancestor

By HospiMedica staff writers
Posted on 14 Jan 2008
A married couple who sailed from England to America around 1630 may be the ancestors of hundreds of people alive today who are at risk for a hereditary form of colon cancer.

Researchers from the Huntsman Cancer Institute (HCI) at the University of Utah (Salt Lake City, USA) studied two large families, one in Utah (USA) and one in New York (USA), that carry a specific genetic mutation that causes a condition called attenuated familial adenomatous polyposis (AFAP). More...
Without proper clinical care, people with the AFAP mutation have a greater than two in three risk of colon cancer by age 80, compared to about one in 24 for the general population. The researchers discovered that the two families share common ancestors, a couple who came to America from England in the 1630s, about the time of the Pilgrims.

The Utah family in this study has more than 7,000 descendants spanning nine generations recorded in the Utah population database (UPDB). Members of this one family account for 0.15% of all colorectal cancers reported in Utah from 1966 to 1995. Based on that percentage, researchers expected to see eight cases of colon cancer from this one family among the over 5,000 reported between 1996 and 2003; but after previous research identified this family as affected by AFAP, aggressive education and clinical intervention resulted in only one mutation carrier in the family being diagnosed with colon cancer during those years. The study was published in the January 2008 issue of the journal Clinical Gastroenterology and Hepatology.

"The fact that this mutation can be traced so far back in time suggests that it could be carried by many more families in the United States than is currently known,” said lead author Deborah Neklason, Ph.D. "In fact, this founder mutation might be related to many colon cancer cases in the United States.”

Clinical recognition of AFAP can be difficult because AFAP-related colon cancer develops on average around 50 years of age, as do sporadic (non-hereditary) colon cancers. About one-third of people with AFAP also have only a few polyps, again similar to that for sporadic colon cancer, and they may also have a limited family history.


Related Links:
University of Utah

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.